Nestle's ProciseDx inks technology deal with Lumiphore

By staff writers

October 10, 2019 -- Nestlé Health Science subsidiary ProciseDx is set to use Lumiphore's metal luminescent reporter technology in a broad range of rapid point-of-care (POC) diagnostics, which will be developed initially for inflammatory and autoimmune conditions, including celiac disease.

ProciseDx instrument with reagent cartridge
The ProciseDx instrument (about 8 inches wide) with reagent cartridge. Image courtesy of ProciseDx.

In a statement, the companies said that advantages of Lumiphore's proprietary lanthanide technology over competing methods include detection sensitivity, simplicity of use, and lower costs for reagents and labor.

ProciseDx announced in September that its ProciseDx instrument had received the CE Mark in Europe and that it was conducting U.S. trials to support filings for the instrument and several assays in the first quarter of 2020. At the time, ProciseDx said it had been working in "stealth mode with Nestlé's support" for three years to develop the POC diagnostic platform. In the statement about the Lumiphore deal, the company said it is excited to bring its point-of-care diagnostics to market in 2020.

The ProciseDx management team includes CEO Larry Mimms, former chief scientific officer at Prometheus Laboratories, which used to be part of Nestlé. Nestlé closed the sale of Prometheus Laboratories to a San Diego-based biotech company called Precision IBD at the end of June but retained the POC diagnostics part of the Prometheus business.

Celiac study reinforces need for appropriate testing
Children who are genetically predisposed to celiac disease and have too much gluten in early childhood are at greater risk of getting the condition, according...
Progentec wins NIH grant for lupus blood tests
Progentec Diagnostics is set to receive $225,000 initially and up to $1.7 million in total through a grant from the U.S. National Institutes of Health...

Copyright © 2019

Last Updated eh 10/10/2019 1:01:45 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.